Nymox Reports Positive Results From Combined Statistical Analysis of Long Term Follow-Up Studies of BPH Drug

NymoxPharmaceutical Corporation (Nasdaq: NYMX) reported positive results from anew study of long-term treatment outcomes for men who had received a singleinjection of NX-1207 2.5 mg for treatment for their benign prostatichyperplasia (BPH). The study analysis found that a statistically significantgreater number of men who had received NX-1207 2.5 mg reported positivetreatment outcomes as compared to men who had received a placebo. The studyinvolved the latest available blinded follow-up study data (an average of 57months post-injection) from the completed clinical trials for thesetreatment groups. A positive treatment outcome was seen if the patient wasnot using other BPH medications and no surgical treatment (including MIST)for BPH was reported at any time during the post-injection follow-up period.